VIR BIOTECHNOLOGY ANNOUNCES EXPANDED PHASE 2 SOLSTICE DATA FOR ELEBSIRAN AND TOBEVIBART IN CHRONIC HEPATITIS DELTA, SHOWING DEEP AND SUSTAINED VIRAL SUPPRESSION, AND EXPLORATORY FINITE TREATMENT DATA

Reuters · 1d ago

Please log in to view news